Home > Journals > Medicine > European Journal of Dermatology > summary
 
      Advanced search    Shopping cart    French version 
 
Latest books
Catalogue/Search
Collections
All journals
Medicine
European Journal of Dermatology
- Current issue
- Archives
- Subscribe
- Order an issue
- More information
Biology and research
Public health
Agronomy and biotech.
My account
Forgotten password?
Online account   activation
Subscribe
Licences IP
- Instructions for use
- Estimate request form
- Licence agreement
Order an issue
Pay-per-view articles
Newsletters
How can I publish?
Journals
Books
Help for advertisers
Foreign rights
Book sales agents



 

Texte intégral de l'article
 
Printable version

Effectiveness of a new therapeutic regimen with albendazole in cutaneous larva migrans


European Journal of Dermatology. Volume 9, Number 5, 352-3, July - August 1999, Thérapeutique

Free Article  

Author(s) : S. Veraldi, G. Rizzitelli

Summary : Twenty-four (13 males and 11 females) adult Caucasian patients affected by cutaneous larva migrans, characterized by extensive and/or multiple lesions, were treated with oral albendazole according to a new therapeutic regimen (400 mg/day for 7 days). No other topical or systemic drug was used nor any physical treatment. All patients were cured at the end of the therapy. No recurrence was observed. No side effect was either complained of or observed, nor was any laboratory abnormality recorded. On the basis of this study, albendazole is effective in cutaneous larva migrans characterized by extensive and/or multiple lesions. This new therapeutic regimen avoids no response and recurrence, which are not uncommonly observed following shorter (e.g.: 1-5 days) therapies with albendazole. The longer duration of the therapy is not accompanied by the appearance of more severe and/or new side effects or laboratory abnormalities.

Keywords : cutaneous larva migrans, albendazole.

 

About us - Contact us - Conditions of use - Secure payment
Latest news - Conferences
Copyright © 2007 John Libbey Eurotext - All rights reserved
[ Legal information - Powered by Dolomède ]